Meb Pharma Consultancy (Opc) Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 0.37%
- Profit Growth -20.55%
- Ebitda -17.42%
- Net Worth 12.45%
- Total Assets -4.60%
About Meb Pharma Consultancy (Opc)
Meb Pharma Consultancy (Opc) Private Limited (MPCOPL) is a Company incorporated in India on 06 September 2019 (Five years and five months 18 days old ). Its registered office is in Nagpur, Maharashtra.
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mangesh Bhad serves as a director at the Company.
Company Details
- Location Nagpur, Maharashtra
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24290MH2019OPC330254
- Company No.
330254
- Incorporation Date
06 Sep 2019
- Date of AGM
-
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Meb Pharma Consultancy (Opc)?
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mangesh Bhad  | Director | 06-Sep-2019 | Current |
Financial Performance of Meb Pharma Consultancy (Opc).
Meb Pharma Consultancy (Opc) Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 0.37% increase. The company also saw a substantial fall in profitability, with a 20.55% decrease in profit. The company's net worth Soared by an impressive increase of 12.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Meb Pharma Consultancy (Opc)?
Unlock access to Meb Pharma Consultancy (Opc)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Meb Pharma Private LimitedMangesh Bhad is a mutual person
Oracity Life Sciences LlpMangesh Bhad is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Meb Pharma Consultancy (Opc)?
Unlock and access historical data on people associated with Meb Pharma Consultancy (Opc), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Meb Pharma Consultancy (Opc), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Meb Pharma Consultancy (Opc)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.